Suppliers in Minnetonka, MN
10 Medicare Suppliers found. Showing 1 - 10
 Cvs Pharmacy #16695 Durable Medical Equipment & Medical Supplies Location: 4848 County Rd 101, Minnetonka, Minnesota 55345 Phone: (952) 401-3814 |
Cvs Pharmacy #16027 Durable Medical Equipment & Medical Supplies Location: 13201 Ridgedale Dr, Minnetonka, Minnesota 55305 Phone: (952) 542-8266 |
Cub Pharmacy #1916 Durable Medical Equipment & Medical Supplies Location: 4801 County Road 101, Minnetonka, Minnesota 55345 Phone: (651) 451-1113 |
Walgreens #13853 Durable Medical Equipment & Medical Supplies Location: 4950 County Rd 101, Minnetonka, Minnesota 55345 Phone: (952) 938-3566 |
Anodyne, Inc. Durable Medical Equipment & Medical Supplies Location: 6024 Blue Circle Dr, Minnetonka, Minnesota 55343 Phone: (952) 546-5334 |
Norstrom Prosthetic/Orthotic Supplier Location: 12401 Wayzata Blvd, Minnetonka, Minnesota 55305 Phone: (651) 900-6800 |
Park Nicollet Health Care Products Durable Medical Equipment & Medical Supplies Location: 15111 Twelve Oaks Center Dr, Minnetonka, Minnesota 55305 Phone: (952) 993-4500 |
Imis Minnesota Inc Eyewear Supplier (Equipment, not the service) Location: 1601 Plymouth Rd, Minnetonka, Minnesota 55343 Phone: (952) 546-4414 |
Visionworks Eyewear Supplier (Equipment, not the service) Location: 12701 Wayzata Blvd, Minnetonka, Minnesota 55305 Phone: (952) 545-6446 |
Lenscrafters #327 Eyewear Supplier (Equipment, not the service) Location: 12513 Wayzata Blvd, Minnetonka, Minnesota 55305 Phone: (952) 591-1966 |
News Archive
New technique transforms iPS cells into natural tumor killers
A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan's flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.
QRxPharma raises A$25 million, announces A$10.4 million Rights Issue
QRxPharma Limited is pleased to announce the successful completion of a placement to institutions and professional investors raising A$25 million which was significantly oversubscribed. The Placement was very well supported by both existing and new investors including Australia, US and UK based fund managers.
Enzyme Research journal publishes new peer-reviewed article involving Protandim
LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.
Lancet neonatal survival series
Three million of the four million newborn babies who die worldwide each year could be saved by low-tech and low-cost interventions, concludes a landmark series of articles published online by The Lancet (Thursday March 3, 2005).
› Verified 3 days ago